Review



skeletal muscle cell growth medium  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    PromoCell skeletal muscle cell growth medium
    Skeletal Muscle Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 371 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Growth+Medium/bio_rxiv__64898__2026__05__06__722928-65-4-9
    Average 96 stars, based on 371 article reviews
    skeletal muscle cell growth medium - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Commitment to Myogenic Differentiation Significantly Aggravates the RNA Phenotype in Myotonic Dystrophy Type 1
    Article Snippet: .. Human immortalised myoblasts were cultured in a 1:1 mix of skeletal muscle cell growth medium (Promocell; Heidelberg, Germany) and Ham's F‐10 nutrient mix (Gibco, Carlsbad, CA, USA), supplemented with 20% (v/v) Hyclone Bovine Growth Serum (Cytiva) and GlutaMax (Gibco). .. Cells were propagated in adherent plastic culture flasks coated with 0.1% gelatin (Sigma‐Aldrich).

    Article Title: Intrinsic IL-6 expression reduces rhIL-6-induced JAK/STAT activation and promotes glucose and oleic acid oxidation in cultured human myoblasts
    Article Snippet: .. Cells were resuspended in Skeletal Muscle Cell Growth Medium (PromoCell), seeded into a collagen-coated flask, cultured at 37°C and 5% CO 2 , and used for experiments in the proliferative phase. ..

    other:

    Article Title: Unveiling FLNC variants: iPSC-derived myogenic cells as a model to study disease mechanisms
    Article Snippet: Upon 100% confluency the human skeletal muscle cell growth medium (PromoCell ® ) was replaced gradually with skeletal muscle differentiation medium (PromoCell ® ) supplemented with 1X ITS-X (GibcoTM), 1X N-2 Supplement (GibcoTM) and 5μM of the TGF-ß inhibitor SB431542.

    Article Title: Identification and functional validation of intracellular protein partners of phosphorothioate splice-switching oligonucleotides using AP-MS
    Article Snippet: KM571 cells were grown in a 50:50 mix of skeletal muscle cell growth medium (Promocell, Germany) and F-10 (Thermo Fisher Scientific, USA), completed with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (100 U/mL).



    Similar Products

    96
    PromoCell skeletal muscle cell growth medium
    Skeletal Muscle Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Growth+Medium/bio_rxiv__64898__2026__05__06__722928-65-4-9
    Average 96 stars, based on 1 article reviews
    skeletal muscle cell growth medium - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    PromoCell growth medium
    Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Differentiation+Medium/pm42087225-67-3-21
    Average 96 stars, based on 1 article reviews
    growth medium - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    PromoCell skeletal muscle cell growth medium kits
    Skeletal Muscle Cell Growth Medium Kits, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Growth+Medium/bio_rxiv__64898__2026__04__27__721147-25-0-11
    Average 96 stars, based on 1 article reviews
    skeletal muscle cell growth medium kits - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    PromoCell proliferation medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Proliferation Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Growth+Medium/bio_rxiv__64898__2026__04__13__718206-131-50-55
    Average 96 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    PromoCell medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Growth+Medium/bio_rxiv__64898__2026__04__13__718206-131-8-10
    Average 96 stars, based on 1 article reviews
    medium - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    PromoCell muscle biopsy
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Muscle Biopsy, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skeletal+muscle+cell+growth+medium/Skeletal+Muscle+Cell+Growth+Medium/bio_rxiv__64898__2026__04__13__718206-131-1-10
    Average 96 stars, based on 1 article reviews
    muscle biopsy - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Journal: bioRxiv

    Article Title: Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment

    doi: 10.64898/2026.04.13.718206

    Figure Lengend Snippet: Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Article Snippet: The muscle biopsy was enzymatically digested in basal medium (C-23060; PromoCell, Heidelberg, Germany) containing collagenase D (2 mg/mL, Roche, Germany) and Dispase II (2 mg/mL, Sigma) for 1 h at 37°C with trituration every 15 min. After filtering through a 100-μm filter (BD Falcon) and centrifugation cells were resuspended in proliferation medium (15% FBS, C-23060; PromoCell, Heidelberg, Germany) and transferred to a T-25 tissue culture vessel (Nunc, Germany).

    Techniques: Derivative Assay, Staining, Concentration Assay, Cell Culture, Cell Characterization, Control, Quantitative RT-PCR, Comparison